Regeneron's Answer to the Biggest Problem With Ozempic
GLP-1 drugs like Ozempic are great at burning fat, but they chew through muscle too. Regeneron's new antibody trevogrumab cut that muscle loss in half when paired with semaglutide, and it could reshape how we think about obesity treatment entirely.
The Ozempic Problem Nobody Wants to Talk About
GLP-1 weight-loss drugs like semaglutide are miracle workers at melting fat. But they have a dirty secret: they eat your muscle, too.
In clinical trials, roughly 25%–40% of the weight people lose on semaglutide comes from lean mass, not fat, with many studies clustering around 39–40%. That includes muscle tissue, the stuff that keeps you strong, mobile, and metabolically healthy. It's like hiring a contractor to renovate your kitchen and finding out he also ripped out the plumbing.
For younger, otherwise healthy patients, losing some muscle during rapid weight loss is manageable. For older adults, or people already at risk of frailty, it's a serious clinical concern. The obesity medicine community has been searching for a fix since GLP-1s exploded onto the scene. On Thursday, Regeneron said it might have one.
Half the Muscle Loss, Same Fat Burn
Regenerons experimental antibody trevogrumab, when added to semaglutide, cut lean-mass loss roughly in half compared to semaglutide alone. The data come from the Phase 2 COURAGE trial, which enrolled adults with obesity and tracked body composition over 52 weeks.
The numbers tell a clean story. Patients on semaglutide plus placebo lost 7.3% of their lean mass over a year. Those who got the higher dose of trevogrumab (75 mg) alongside semaglutide lost only 4.2%. The lower dose (25 mg) landed in between at 5.8%.
But the really striking finding came from MRI scans of patients' thighs. In that substudy, trevogrumab preserved roughly 70% of the thigh muscle volume that would have otherwise disappeared on semaglutide alone. Think of it this way: if semaglutide normally costs you ten pounds of muscle, trevogrumab gives you seven of those pounds back.
And here's what makes the data especially interesting: trevogrumab didn't boost total weight loss. Patients lost about the same number of pounds whether they got the antibody or not. The drug isn't making you lose more weight; it's making you lose weight. More fat, less muscle. Quality over quantity.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
better
How It Works (Without a Biochemistry Degree)
Your body has a protein called myostatin (also known as GDF8) that acts like a governor on an engine. Its job is to limit how much muscle you build. In evolutionary terms, that made sense: muscle is expensive tissue to maintain, and our ancestors couldn't afford to carry more than they needed.
Trevogrumab is a monoclonal antibody that blocks myostatin. Remove the governor, and your body shifts the balance away from muscle breakdown and toward muscle preservation. It's selective, too; unlike some competing approaches that block multiple growth-factor signals at once, trevogrumab targets myostatin specifically without interfering with related proteins like activin A or GDF11.
Regenerons scientists originally developed this antibody (initially called REGN1033) in preclinical work where it increased muscle mass and improved muscle strength in mice, including older mice that had already started losing muscle. The leap from mouse cages to human obesity clinics took years, but the COURAGE data suggest the concept translates.
The Safety Question That Could Make or Break It
Any time you add a second drug to a regimen, the first question is tolerability. On that front, trevogrumab looks surprisingly clean.
Adverse events were actually reported in a lower percentage of trevogrumab-treated patients (77%) than in the semaglutide-plus-placebo group (82%). That's an unusual and encouraging signal for a combination therapy, though the trial was relatively small, and Phase 2 numbers should always be interpreted with caution.
There is a caveat, though. Regeneron is also testing a more aggressive three-drug approach: semaglutide plus trevogrumab plus garetosmab, an antibody against activin A. That triplet regimen showed even more muscle preservation, but it also had higher dropout rates due to side effects. The commercial sweet spot, at least for now, appears to be the simpler two-drug combo.
A $30 Billion Opportunity Hiding Inside the Obesity Market
Wall Street has been watching the muscle-preservation space closely, and analysts are putting real numbers on the opportunity. Reuters cited forecasts suggesting that muscle-sparing obesity therapies could reach $30 billion in annual sales by 2035.
That number sounds enormous, but consider the context. The global GLP-1 market is already generating tens of billions annually and growing fast. If a meaningful fraction of those patients (especially older ones, or those with sarcopenic obesity) could benefit from an add-on that protects their muscle, the addressable market is massive.
For Regeneron specifically, the stock carries an average analyst target around $802–$810 with a consensus "Moderate Buy" recommendation. Those figures reflect Regeneron's entire business (including Dupixent and Eylea), but analysts are clearly assigning meaningful value to the obesity pipeline.
The Competition Is Coming
Regenerons not the only company chasing this prize. The most advanced competitor is bimagrumab, an antibody developed initially by Novartis that blocks activin type II receptors. Instead of just targeting myostatin, bimagrumab casts a wider net, blocking multiple ligands that suppress muscle growth.
Bimagrumab has shown something Regeneron's drug hasn't: the ability to increase lean mass while simultaneously reducing fat. It's been studied in combination with semaglutide in the BELIEVE trial, and the body-recomposition data are compelling. The tradeoff? Blocking multiple signals at once raises more safety and tolerability questions than a targeted approach.
There are also other myostatin-selective drugs in development, including apitegromab, which takes a slightly different angle on the same pathway. The race to become the standard muscle-preservation add-on to GLP-1 therapy is genuinely competitive.
The strategic question is whether doctors and patients will prefer a targeted, potentially safer approach (trevogrumab) or a broader, potentially more powerful one (bimagrumab). It's the precision-versus-power debate that plays out across all of medicine.
Regeneron's Bigger Obesity Playbook
Trevogrumab isn't a one-off bet. Regeneron is building an entire combination-therapy portfolio around the idea that the future of obesity treatment isn't a single pill or injection; it's a carefully layered regimen.
The pieces include: olatorepatide, a dual GLP-1/GIP receptor agonist licensed from Hansoh that serves as Regeneron's own incretin backbone; the trevogrumab muscle-preservation layer; garetosmab for additional muscle protection in patients who need it; and mibavademab, another combination candidate being tested with tirzepatide.
The company has signaled plans for additional Phase 2 work in older adults with obesity and low muscle mass. If those studies and further trials confirm the COURAGE findings, Regeneron could be filing for approval within a few years.
The vision is a modular obesity platform. Start with an incretin drug for weight loss, add trevogrumab to protect muscle, layer on garetosmab if more preservation is needed, and potentially combine with therapies for related conditions like high cholesterol. It's the Lego approach to obesity medicine: snap together the pieces each patient needs.
Why This Matters Beyond the Stock Ticker
The conversation around GLP-1 drugs has been dominated by one metric: how many pounds can you lose? That framing misses something important. Not all weight loss is created equal.
Losing 50 pounds of mostly fat is a medical triumph. Losing 50 pounds where a third of it is muscle could leave a patient weaker, more prone to falls, and metabolically worse off in ways that don't show up on a bathroom scale. This is especially true for the millions of older adults who are candidates for GLP-1 therapy but also at risk for sarcopenia (age-related muscle wasting).
Regenerons COURAGE data don't solve the problem completely. Even with the high dose of trevogrumab, patients still lost 4.2% of their lean mass over a year. That's meaningfully better than 7.3%, but it's not zero. And we still don't have long-term data on whether preserved muscle translates into better functional outcomes: fewer falls, more strength, improved quality of life.
But the direction is clear. The next chapter of the obesity revolution won't be about losing more weight. It'll be about losing the right weight. Regeneron just wrote one of the first pages.
Deals & M&A
4 min read
Bayer Just Bet $2.2 Billion That Ohio Is the Future of Pharma
Bayer is pouring $2.2 billion into its first-ever North American pharma manufacturing campus in Ohio. The move signals the German giant's biggest bet yet on U.S.-made drugs, but the factory won't produce a single pill until 2031.
